These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19026650)

  • 1. High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay.
    Zou H; Taylor WR; Harrington JJ; Hussain FT; Cao X; Loprinzi CL; Levine TR; Rex DK; Ahnen D; Knigge KL; Lance P; Jiang X; Smith DI; Ahlquist DA
    Gastroenterology; 2009 Feb; 136(2):459-70. PubMed ID: 19026650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-resolution melting assay (HRMA) is a simple and sensitive stool-based DNA Test for the detection of mutations in colorectal neoplasms.
    Li BS; Wang XY; Xu AG; Ma FL; Ma QY; Li Z; Liu JH; Gan AH; Yu ZJ; Zhang XH; Jiang B
    Clin Colorectal Cancer; 2012 Dec; 11(4):280-90. PubMed ID: 22609129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multitarget stool DNA testing for colorectal-cancer screening.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Levin TR; Lavin P; Lidgard GP; Ahlquist DA; Berger BM
    N Engl J Med; 2014 Apr; 370(14):1287-97. PubMed ID: 24645800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Detection of Colorectal Cancer: a Multi-Center Pre-Clinical Case Cohort Study for Validation of a Combined DNA Stool Test.
    Dollinger MM; Behl S; Fleig WE
    Clin Lab; 2018 Oct; 64(10):1719-1730. PubMed ID: 30336540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stool DNA and occult blood testing for screen detection of colorectal neoplasia.
    Ahlquist DA; Sargent DJ; Loprinzi CL; Levin TR; Rex DK; Ahnen DJ; Knigge K; Lance MP; Burgart LJ; Hamilton SR; Allison JE; Lawson MJ; Devens ME; Harrington JJ; Hillman SL
    Ann Intern Med; 2008 Oct; 149(7):441-50, W81. PubMed ID: 18838724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Highly methylated genes in colorectal neoplasia: implications for screening.
    Zou H; Harrington JJ; Shire AM; Rego RL; Wang L; Campbell ME; Oberg AL; Ahlquist DA
    Cancer Epidemiol Biomarkers Prev; 2007 Dec; 16(12):2686-96. PubMed ID: 18086775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia.
    Tagore KS; Lawson MJ; Yucaitis JA; Gage R; Orr T; Shuber AP; Ross ME
    Clin Colorectal Cancer; 2003 May; 3(1):47-53. PubMed ID: 12777192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of APC mutations in fecal DNA from patients with colorectal tumors.
    Traverso G; Shuber A; Levin B; Johnson C; Olsson L; Schoetz DJ; Hamilton SR; Boynton K; Kinzler KW; Vogelstein B
    N Engl J Med; 2002 Jan; 346(5):311-20. PubMed ID: 11821507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation stool DNA test accurately detects colorectal cancer and large adenomas.
    Ahlquist DA; Zou H; Domanico M; Mahoney DW; Yab TC; Taylor WR; Butz ML; Thibodeau SN; Rabeneck L; Paszat LF; Kinzler KW; Vogelstein B; Bjerregaard NC; Laurberg S; Sørensen HT; Berger BM; Lidgard GP
    Gastroenterology; 2012 Feb; 142(2):248-56; quiz e25-6. PubMed ID: 22062357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population.
    Imperiale TF; Ransohoff DF; Itzkowitz SH; Turnbull BA; Ross ME;
    N Engl J Med; 2004 Dec; 351(26):2704-14. PubMed ID: 15616205
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS mutations and M2PK upregulation in stool samples from individuals with positive fecal occult blood tests screened for colorectal cancer.
    Battaglia P; Baritono E; Remo A; Vendraminelli R; Conti A
    Tumori; 2014; 100(2):122-7. PubMed ID: 24852854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of microsatellite instability, CpG island methylation phenotype, BRAF and KRAS status in serrated polyps and traditional adenomas indicates separate pathways to distinct colorectal carcinoma end points.
    O'Brien MJ; Yang S; Mack C; Xu H; Huang CS; Mulcahy E; Amorosino M; Farraye FA
    Am J Surg Pathol; 2006 Dec; 30(12):1491-501. PubMed ID: 17122504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA methylation of phosphatase and actin regulator 3 detects colorectal cancer in stool and complements FIT.
    Bosch LJ; Oort FA; Neerincx M; Khalid-de Bakker CA; Terhaar sive Droste JS; Melotte V; Jonkers DM; Masclee AA; Mongera S; Grooteclaes M; Louwagie J; van Criekinge W; Coupé VM; Mulder CJ; van Engeland M; Carvalho B; Meijer GA
    Cancer Prev Res (Phila); 2012 Mar; 5(3):464-72. PubMed ID: 22135045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Combined use of Fecal Multigene Mutation Test and Fecal Immunochemical Test for Colorectal Cancer Screening.
    Chen J; Lin J; Zhang L; Chen M; Yu X; Wu Y; Wang T; Xu R; Tian T; Sun A; Zhang T; Lu Y; Ba Z; Cheng X; Chen M
    Clin Lab; 2022 Dec; 68(12):. PubMed ID: 36546736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Highly sensitive stool DNA testing of Fusobacterium nucleatum as a marker for detection of colorectal tumours in a Japanese population.
    Suehiro Y; Sakai K; Nishioka M; Hashimoto S; Takami T; Higaki S; Shindo Y; Hazama S; Oka M; Nagano H; Sakaida I; Yamasaki T
    Ann Clin Biochem; 2017 Jan; 54(1):86-91. PubMed ID: 27126270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome.
    Flanagan L; Schmid J; Ebert M; Soucek P; Kunicka T; Liska V; Bruha J; Neary P; Dezeeuw N; Tommasino M; Jenab M; Prehn JH; Hughes DJ
    Eur J Clin Microbiol Infect Dis; 2014 Aug; 33(8):1381-90. PubMed ID: 24599709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analytical sensitivity and stability of DNA methylation testing in stool samples for colorectal cancer detection.
    Bosch LJ; Mongera S; Terhaar Sive Droste JS; Oort FA; van Turenhout ST; Penning MT; Louwagie J; Mulder CJ; van Engeland M; Carvalho B; Meijer GA
    Cell Oncol (Dordr); 2012 Aug; 35(4):309-15. PubMed ID: 22821210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting colorectal cancer in stool with the use of multiple genetic targets.
    Dong SM; Traverso G; Johnson C; Geng L; Favis R; Boynton K; Hibi K; Goodman SN; D'Allessio M; Paty P; Hamilton SR; Sidransky D; Barany F; Levin B; Shuber A; Kinzler KW; Vogelstein B; Jen J
    J Natl Cancer Inst; 2001 Jun; 93(11):858-65. PubMed ID: 11390535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
    Smith A; Young GP; Cole SR; Bampton P
    Cancer; 2006 Nov; 107(9):2152-9. PubMed ID: 16998938
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant mutations and splice variants in KRAS and BRAF demonstrate complex perturbation of the Ras/Raf signalling pathway in advanced colorectal cancer.
    Seth R; Crook S; Ibrahem S; Fadhil W; Jackson D; Ilyas M
    Gut; 2009 Sep; 58(9):1234-41. PubMed ID: 19474002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.